Hany Refaat, Dawlat Sany, Amr Mohab, Haitham Ezzat
{"title":"Comparing Dialysis Modality and Cardiovascular Mortality in Patients on Hemodialysis and Peritoneal Dialysis.","authors":"Hany Refaat, Dawlat Sany, Amr Mohab, Haitham Ezzat","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Patients undergoing dialysis are at high risk for cardiovascular disease (CVD). Mortality differences between peritoneal dialysis (PD) and hemodialysis (HD) are widely debated. The question of whether dialysis modality affects the risk for CVD remains to be addressed.In the present study, we evaluated the influence of hemodialysis (HD) and peritoneal dialysis (PD) on survival and the risk of developing de novo CVD. Our observational prospective study enrolled 157 end-stage renal disease patients on HD or PD for 12 months. Patients with a history of malignancy, chronic rheumatic heart disease, congenital heart disease, previous cardiac surgery, or previous transplantation, and patients started on dialysis less than 3 months earlier were excluded from the study. Detailed medical history, demographic data, and routine laboratory investigations were obtained, and patients were follow every 3 months for 12 months. Cardiac echography was performed at baseline and at 6 months. Nutrition status was scored using the standardized 7-point subjective global assessment (SGA). Baseline comorbidities included the presence or absence of coronary artery disease (angina, myocardial infarction, and coronary artery bypass surgery), peripheral vascular disease, hypertension, diabetes mellitus, and cerebrovascular disease.Of the 157 patients, 121 were on HD (60 men, 61 women; mean age: 59.3 years), and 36 were on PD (14 men, 22 women; mean age: 50.8 years, p = 0.13). The dialysis duration was significantly different in the two groups (HD: 52.96 ± 38.3; PD: 30.89 ± 26.3; p = 0.02). Of the HD patients, 95.04% were hypertensive, and 61.98% were diabetic; of the PD patients, 91.66% were hypertensive, and 50% were diabetic. Body mass index and SGA score were not significantly different between the two groups. Patients on PD had a higher residual urine volume (383.66 ± 548.393 mL vs. 12.40 ± 96.238 mL in the HD patients, p < 0.001).In comparing traditional cardiovascular risk factors at the start of the study, PD patients had higher levels of total cholesterol (4.5 ± 1.33 mmol/L vs. 3.85 ± 1.34 mmol/L in HD patients, p < 0.05), low-density lipoprotein cholesterol (2.84 ± 1.31 mmol/L vs. 2.06 ± 0.89 mmol/L, p < 0.001), high-density lipoprotein cholesterol (1.10 ± 0.26 mmol/L vs. 0.91 ± 0.32 mmol/L, p < 0.005). Cardiovascular morbidity affected 17 HD patients and 2 PD patients. A Cox proportional hazards model for cardiovascular events showed a trend suggesting that PD was safer, but the data did not reach statistical significance. Kaplan-Meir survival analysis revealed 12 death events in HD patients compared with 4 events in PD patients-a difference that was not statistically significant.Cardiovascular morbidity during chronic dialysis was prevalent among the older patients (>57 years) and those who used more than 1 antihypertensive medication; an ejection fraction exceeding 53% was found to be cardioprotective. For all-cause mortality, dialysis modality was a nonsignificant risk factor; age and Kt/V were significant.</p>","PeriodicalId":7361,"journal":{"name":"Advances in peritoneal dialysis. Conference on Peritoneal Dialysis","volume":"32 ","pages":"22-31"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in peritoneal dialysis. Conference on Peritoneal Dialysis","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Patients undergoing dialysis are at high risk for cardiovascular disease (CVD). Mortality differences between peritoneal dialysis (PD) and hemodialysis (HD) are widely debated. The question of whether dialysis modality affects the risk for CVD remains to be addressed.In the present study, we evaluated the influence of hemodialysis (HD) and peritoneal dialysis (PD) on survival and the risk of developing de novo CVD. Our observational prospective study enrolled 157 end-stage renal disease patients on HD or PD for 12 months. Patients with a history of malignancy, chronic rheumatic heart disease, congenital heart disease, previous cardiac surgery, or previous transplantation, and patients started on dialysis less than 3 months earlier were excluded from the study. Detailed medical history, demographic data, and routine laboratory investigations were obtained, and patients were follow every 3 months for 12 months. Cardiac echography was performed at baseline and at 6 months. Nutrition status was scored using the standardized 7-point subjective global assessment (SGA). Baseline comorbidities included the presence or absence of coronary artery disease (angina, myocardial infarction, and coronary artery bypass surgery), peripheral vascular disease, hypertension, diabetes mellitus, and cerebrovascular disease.Of the 157 patients, 121 were on HD (60 men, 61 women; mean age: 59.3 years), and 36 were on PD (14 men, 22 women; mean age: 50.8 years, p = 0.13). The dialysis duration was significantly different in the two groups (HD: 52.96 ± 38.3; PD: 30.89 ± 26.3; p = 0.02). Of the HD patients, 95.04% were hypertensive, and 61.98% were diabetic; of the PD patients, 91.66% were hypertensive, and 50% were diabetic. Body mass index and SGA score were not significantly different between the two groups. Patients on PD had a higher residual urine volume (383.66 ± 548.393 mL vs. 12.40 ± 96.238 mL in the HD patients, p < 0.001).In comparing traditional cardiovascular risk factors at the start of the study, PD patients had higher levels of total cholesterol (4.5 ± 1.33 mmol/L vs. 3.85 ± 1.34 mmol/L in HD patients, p < 0.05), low-density lipoprotein cholesterol (2.84 ± 1.31 mmol/L vs. 2.06 ± 0.89 mmol/L, p < 0.001), high-density lipoprotein cholesterol (1.10 ± 0.26 mmol/L vs. 0.91 ± 0.32 mmol/L, p < 0.005). Cardiovascular morbidity affected 17 HD patients and 2 PD patients. A Cox proportional hazards model for cardiovascular events showed a trend suggesting that PD was safer, but the data did not reach statistical significance. Kaplan-Meir survival analysis revealed 12 death events in HD patients compared with 4 events in PD patients-a difference that was not statistically significant.Cardiovascular morbidity during chronic dialysis was prevalent among the older patients (>57 years) and those who used more than 1 antihypertensive medication; an ejection fraction exceeding 53% was found to be cardioprotective. For all-cause mortality, dialysis modality was a nonsignificant risk factor; age and Kt/V were significant.
接受透析的患者患心血管疾病(CVD)的风险很高。腹膜透析(PD)和血液透析(HD)的死亡率差异存在广泛争议。透析方式是否影响心血管疾病风险的问题仍有待解决。在本研究中,我们评估了血液透析(HD)和腹膜透析(PD)对生存和发展为新生心血管疾病风险的影响。我们的观察性前瞻性研究招募了157名患有HD或PD的终末期肾病患者,为期12个月。有恶性肿瘤史、慢性风湿性心脏病、先天性心脏病、既往心脏手术或既往移植史以及透析开始时间少于3个月的患者被排除在研究之外。获得详细的病史、人口统计资料和常规实验室检查,每3个月随访一次,随访12个月。在基线和6个月时进行心脏超声检查。采用标准化的7分主观整体评估(SGA)对营养状况进行评分。基线合并症包括是否存在冠状动脉疾病(心绞痛、心肌梗死和冠状动脉搭桥手术)、周围血管疾病、高血压、糖尿病和脑血管疾病。157例患者中,121例患有HD(60例男性,61例女性;平均年龄:59.3岁),36人接受PD治疗(男性14人,女性22人;平均年龄:50.8岁,p = 0.13)。两组患者透析时间差异有统计学意义(HD: 52.96±38.3;Pd: 30.89±26.3;P = 0.02)。高血压患者占95.04%,糖尿病患者占61.98%;PD患者中高血压占91.66%,糖尿病占50%。两组间体重指数和SGA评分差异无统计学意义。PD组残尿量高于HD组(383.66±548.393 mL vs 12.40±96.238 mL, p < 0.001)。在比较研究开始时的传统心血管危险因素时,PD患者的总胆固醇(4.5±1.33 mmol/L比HD患者的3.85±1.34 mmol/L, p < 0.05)、低密度脂蛋白胆固醇(2.84±1.31 mmol/L比2.06±0.89 mmol/L, p < 0.001)、高密度脂蛋白胆固醇(1.10±0.26 mmol/L比0.91±0.32 mmol/L, p < 0.005)水平较高。17例HD患者发生心血管疾病,2例PD患者发生心血管疾病。心血管事件的Cox比例风险模型显示出PD更安全的趋势,但数据没有达到统计学意义。Kaplan-Meir生存分析显示,HD患者有12例死亡事件,PD患者有4例死亡事件,差异无统计学意义。慢性透析期间心血管疾病发病率在年龄较大(>57岁)和使用1种以上降压药的患者中普遍存在;射血分数超过53%被认为具有心脏保护作用。对于全因死亡率,透析方式是不显著的危险因素;年龄和Kt/V有显著性差异。